Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.30 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.30 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248308 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL9422815 | 0.80 | — | — | |
| SCHEMBL23555344 | 0.80 | KDM4E (0.48) | KDM4EKMT2A | |
| SCHEMBL5551595 | 0.78 | — | — | |
| SCHEMBL2087384 | 0.78 | ALDH1A1 (0.40) | KMT2A | |
| SCHEMBL23520425 | 0.77 | KDM4E (0.41) | KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL11818558 | 0.76 | ALDH1A1 (0.33) | — | |
| SCHEMBL5125174 | 0.76 | ALDH1A1 (0.44) | KMT2ATSHR | |
| SCHEMBL2275815 | 0.76 | ALDH1A1 (0.44) | KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL31134228 | 0.76 | GABRP (0.33) | KDM4EKMT2AGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773256-B | Synthesis method of 4-cyano piperidine | 中国农业大学 | 2024-05-03 | — | — | CN | claimed |
| CN-114773256-B | Synthesis method of 4-cyano piperidine | 中国农业大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-114773256-B | Synthesis method of 4-cyano piperidine | 中国农业大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-114773256-A | Synthetic method of 4-cyanopiperidine | 中国农业大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-114773256-A | Synthetic method of 4-cyanopiperidine | 中国农业大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-103249732-B | The bacterial topoisomerase II of suppression 2-ethyl carbamyl amino-1,3-benzothiazole-5-base | 生物区欧洲有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-102186479-A | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC | 2011-09-14 | — | — | CN | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| EP-2029592-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | KDM4E 3411/4885KMT2A 3188/4885GABRP 2600/4885 |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | KDM4E 3386/4885KMT2A 1673/4885GABRP 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.